Day One Biopharmaceuticals, Inc.
DAWN
$6.42
$0.121.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.42% | 34.13% | 58.53% | 76.82% | 47.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.29% | 58.85% | 24.66% | 149.72% | 34.70% |
| Operating Income | 33.51% | -9.77% | 157.61% | -133.09% | -34.70% |
| Income Before Tax | 42.33% | -8.68% | 178.34% | 93.77% | -47.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.33% | -20.55% | 180.25% | 90.39% | -47.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.33% | -20.55% | 180.25% | 90.39% | -47.22% |
| EBIT | 33.51% | -9.77% | 157.61% | -133.09% | -34.70% |
| EBITDA | 34.81% | -8.75% | 158.80% | -132.48% | -34.67% |
| EPS Basic | 51.32% | -1.26% | 171.39% | 91.73% | -22.24% |
| Normalized Basic EPS | 47.10% | 8.71% | 169.70% | 94.64% | -12.47% |
| EPS Diluted | 51.32% | -0.96% | 170.37% | 91.73% | -22.24% |
| Normalized Diluted EPS | 47.10% | 8.71% | 169.46% | 94.64% | -12.47% |
| Average Basic Shares Outstanding | 18.49% | 19.06% | 12.41% | 16.22% | 20.43% |
| Average Diluted Shares Outstanding | 18.49% | 19.06% | 12.78% | 16.22% | 20.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |